- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02110004
Picasso NAV High-Density Mapping Catheter for Signal Analysis of Complex Arrhythmias - First-In-Man
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Aalst, Belgium
- OLV Hospital
-
-
-
-
-
Prague, Czech Republic
- Na Homolce Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria to be eligible for participation in this clinical investigation.
- Age > 18 years or older.
- Patients who have signed the Patient Informed Consent Form (ICF)
- Patients who are scheduled to undergo a clinically-indicated catheter ablation procedure for the management of a complex arrhythmia. (Patients having undergone a previous ablation procedure may be included.)
- Subjects who have failed at least one antiarrhythmic drug (AAD) (including AV nodal blocking agents such as beta blockers and calcium channel blockers) as evidenced by recurrent symptomatic complex arrhythmia, or intolerable to the AAD
- Complex arrhythmias (including atrial fibrillation, atypical flutter, ventricular tachycardia) defined as patients who have been diagnosed with a complex arrhythmia anytime within the last 5 years prior to enrolment. Symptoms may include, but are not restricted to, palpitations, shortness of breath, chest pain, fatigue, left ventricular dysfunction, or other symptoms, or any combination of the above.
- At least one episode of the complex arrhythmia must have been documented by ECG, Holter, loop recorder, telemetry, implanted device, or transtelephonic monitoring within 12 months of enrollment.
- Able and willing to comply with all pre-, post-, and follow-up testing and requirements.
Exclusion Criteria:
Subjects who meet any of the following exclusion criteria are not eligible for enrollment.
- A complex arrhythmia secondary to a reversible cause.
- Atrial arrhythmias: patients with a left atrial size >55 mm (echocardiography, parasternal long axis view).
- Left Ventricular Ejection Fraction < 25%
- NYHA Class III or IV
- Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.
- Atrial arrhythmias: patients with structural atrial disease such as a prior history of atriotomy from prior atrial surgery, presence of an atrial septal defect, and/or presence of an atrial septal closure patch.
- History of or current blood clotting or bleeding abnormalities, contraindication to systemic anticoagulation (i.e., heparin, warfarin, dabigatran, or a direct thrombin inhibitor)
- Subjects that have ever undergone valvular cardiac surgical procedure (ie, ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve)
- Any cardiac surgery within the past 60 days (2 months) (includes PCI)
- Concurrent enrollment in a study evaluating another device or drug.
- A complex arrhythmia secondary to electrolyte imbalance, thyroid disease, or non-cardiac cause.
- Presence of intra-cardiac thrombus or myxoma, interatrial baffle or patch, tumor or other abnormality that precludes catheter introduction or manipulation.
- Presence of a condition that precludes vascular access.
- Women of child bearing potential whom are pregnant, lactating, or planning to become pregnant during the course of the clinical investigation
- Active illness or active systemic infection or sepsis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Ablation procedure
Collect intra-cardiac signals
|
The primary purpose of the First-In-Man clinical investigation is to assess the Picasso NAV Catheter's ability to collect intra-cardiac signals within the desired chambers (atrial and/or ventricle) in the heart for the analysis of complex arrhythmias.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intra-procedural investigational device success
Time Frame: Intra-procedure
|
Intra-procedural investigational device success
Measured by number and percentage of physicians able to deploy and collect intra-cardiac signals as outlined in the protocol |
Intra-procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterize the ideal workflow
Time Frame: Intra-procedure
|
Characterize the ideal workflow (defined as catheter preparation, connectivity, and configuration) and the use of the Picasso NAV Catheter's ability to map areas of interest Measured by survey questions |
Intra-procedure
|
Visualize the device
Time Frame: Up to 3 months
|
Ability to visualize the device Measured by survey questions |
Up to 3 months
|
Overall safety
Time Frame: Up to 7 days
|
Overall safety
Measured by number and percentage of patients experiencing those adverse events |
Up to 7 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tom De Potter, OLV Hospital
- Principal Investigator: Petr Neuzil, Na Homolce Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PIC-152
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arrhythmias
-
Medtronic BRCCompletedAtrial Fibrillation | Risk of Cardiac ArrhythmiasNetherlands, Germany, Austria, Belgium, Canada, Czech Republic, Russian Federation, Slovakia
-
Uri farkashCompletedEvaluation of Cardiac Arrhythmias in Hand Surgery Using Local Anesthesia With AdrenalineIsrael
-
Massachusetts General HospitalTerminated
-
The Leeds Teaching Hospitals NHS TrustCompletedArrhythmiasUnited Kingdom
-
Biosense Webster, Inc.Completed
-
Medtronic Cardiac Rhythm and Heart FailureCompletedCardiac ArrhythmiasAustria, France
-
Instituto de Investigación Sanitaria Gregorio MarañónCatheter Robotics, Inc.Unknown
-
Boston Scientific CorporationCompleted
Clinical Trials on Ablation procedure
-
AtriCure, Inc.CompletedAtrial FibrillationUnited States, Netherlands, Belgium
-
Boston Scientific CorporationCompletedParoxysmal Atrial FibrillationSpain, Germany, Italy
-
Boston Scientific CorporationCompletedParoxysmal Atrial FibrillationUnited Kingdom, Spain, France, Germany
-
Heart Rhythm Clinical and Research Solutions, LLCAttune MedicalNot yet recruiting
-
Heart Rhythm Clinical and Research Solutions, LLCBiosense Webster, Inc.Recruiting
-
Medtronic Cardiac Rhythm and Heart FailureMedtronicCompletedParoxysmal Atrial FibrillationDenmark, Netherlands, Germany, Switzerland
-
University of California, San FranciscoCompletedNeurocognitive DysfunctionUnited States, Canada
-
Cardiovascular Innovation and Research InstituteValley View HospitalRecruitingCoronary Artery Disease | Atrial Fibrillation (AF)United States
-
Vektor MedicalExperien GroupCompletedAtrial Fibrillation | Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Arrythmia | Cardiac Arrhythmia | Premature Ventricular Complexes Multiple | Premature Atrial Complex | Atrioventricular Reentrant TachycardiaUnited States
-
University of AarhusCompletedAtrial Fibrillation | Burden of Atrial FibrillationDenmark